SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Positive Phase 3 DAYBREAK results for Kodiaks wet AMD candidates, including Zenkudas potential for longer intervals between treatments, sparked a sharp rally. Bulls celebrated the clinical progress, while skeptics warned the move may be overextended and debated financing and dilution risks before FDA approval.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing shares are under pressure after the FAA reportedly delayed 737 MAX 10 certification while reviewing a flight-management software glitch that can interrupt automated navigation in a specific missed-approach scenario. Traders disagree on whether it is a manageable software fix or another sign of Boeings execution problems, with certification and delivery concerns weighed against calls that the selloff is overdone.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas major strategic investment in Summit and a clinical collaboration on ivonescimab are driving attention, with traders viewing the deal as financial backing and validation of the cancer drug. Some speculate it could lead to an acquisition, while others stress that it is an equity investment and collaborationnot a buyout.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for a U.S. Army program to develop next-generation 10 kV silicon-carbide power technology is driving attention, with traders viewing it as validation of the companys technology and speculating about a short squeeze. Others caution that the award is a prototype-development project with undisclosed financial terms, so its near-term revenue impact is unclear.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA acceptance of VantageScore for Fannie Mae and Freddie Mac mortgages is fueling concern that competition could weaken FICOs long-standing mortgage-scoring position and pricing power. Bears see the shift, alongside valuation and debt-funded buyback concerns, as a threat to the investment case, while bulls argue FICO remains entrenched and the selloff creates value.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention amid a modest price rebound and ongoing debate over whether Zebecs payroll, card and payments partnerships will translate into sustained token demand. Bulls point to expanding adoption, including enterprise payroll activity on Stellar, while skeptics say the token has lagged despite partnership announcements and want clearer evidence of growing usage and volume.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is drawing attention amid a sharp selloff in long-term Treasuries as yields climb and traders price in higher-for-longer rates, citing persistent inflation, oil-price risks and government debt. Many see further downside if yields keep rising, while others argue the fund is oversold and are accumulating ahead of a possible yield reversal.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is drawing attention after a sharp rally from the low-$50s into the $70s and a subsequent pullback. Traders are split between expecting a breakout and viewing the move as another pump-and-dump, with bullish posts also pointing to ETF-related interest and LitVM while skeptics cite LTCs history of weak follow-through.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Concerns about Red Cats execution dominate, with traders questioning the lack of disclosed orders and revenue despite expanded drone and autonomous-boat operations, and debating the companys standing in Pentagon drone programs. Skeptics fault management and fear further dilution, while some investors remain optimistic about Black Widow and boat-market potential.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonalds shares are under pressure after its investor-day outlook pointed to persistent inflation and weak restaurant traffic alongside a multiyear investment plan, prompting analyst target cuts. Traders debate whether the plans longer-term efficiency and market-share goals can offset near-term sales concerns, while some see the selloff as an oversold buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SPRB anyone here? How does $RARE approval today derisk spruce? Any insights?

StockTwits for iOS

Spruce Biosciences Inc

Ultragenyx Pharmaceutical Inc

 approval today derisk spruce? Any insights?

@Jyoudoit seems like the de-risking is already priced in. Market expects $SPRB will get the FDA approval but the drug itself won&#39;t be worth much - because of the limited patients number and the alternatives (gene therapy) in the future. 
 
So it&#39;s currently priced for Spruce getting the priority voucher (worth maybe $150-200M) and everything else having zero to negative cashflow. Perhaps dilution in 2027-2028 and a couple of years of relatively small revenue. Then revenue will go to zero because of something like JCR Japan or Sangrail. 
 
Good thing is this can still be bought back by $BMRN for 500M+ and it can just squeeze on its own because of the tiny float.

K Kum

StockTwits Web

Biomarin Pharmaceutical Inc. - Registered Shares

 seems like the de-risking is already priced in. Market expects 

 will get the FDA approval but the drug itself won't be worth much - because of the limited patients number and the alternatives (gene therapy) in the future. 
 
So it's currently priced for Spruce getting the priority voucher (worth maybe $150-200M) and everything else having zero to negative cashflow. Perhaps dilution in 2027-2028 and a couple of years of relatively small revenue. Then revenue will go to zero because of something like JCR Japan or Sangrail. 
 
Good thing is this can still be bought back by 

 for 500M+ and it can just squeeze on its own because of the tiny float.